MARKET

OMER

OMER

Omeros
NASDAQ
4.060
-0.170
-4.02%
After Hours: 4.400 +0.34 +8.37% 16:19 06/14 EDT
OPEN
4.240
PREV CLOSE
4.230
HIGH
4.410
LOW
4.040
VOLUME
402.22K
TURNOVER
0
52 WEEK HIGH
7.72
52 WEEK LOW
0.9200
MARKET CAP
235.25M
P/E (TTM)
-2.0591
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at OMER last week (0603-0607)?
Weekly Report · 5d ago
Needham Reiterates Hold on Omeros
Benzinga · 06/04 09:45
Analysts Offer Insights on Healthcare Companies: Sensei Biotherapeutics (SNSE) and Omeros (OMER)
TipRanks · 06/03 18:20
Omeros Shares Rise on Balance Sheet Strengthening
Dow Jones · 06/03 15:33
Omeros Entered Into Credit And Guaranty Agreement to Provide Senior Secured Term Loan Facility Initially Up To $92.1M
Benzinga · 06/03 13:05
OMEROS CORP: ENTERED CREDIT AGREEMENT WHICH PROVIDES FOR A SENIOR SECURED TERM LOAN FACILITY INITIALLY OF UP TO $92.1 MLN
Reuters · 06/03 13:03
OMEROS CORPORATION FURTHER STRENGTHENS ITS BALANCE SHEET THROUGH SERIES OF FINANCING TRANSACTIONS EXTENDING MATURITY ON A MAJORITY OF ITS OUTSTANDING DEBT INTO 2028
Reuters · 06/03 13:00
Weekly Report: what happened at OMER last week (0527-0531)?
Weekly Report · 06/03 12:06
More
About OMER
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.

Webull offers Omeros Corp stock information, including NASDAQ: OMER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMER stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OMER stock methods without spending real money on the virtual paper trading platform.